Citalopram and escitalopram plasma drug and metabolite concentrations: Genome-wide associations

British Journal of Clinical Pharmacology

Volumn 78, Issue 2, 2014, Pages 373-383

  Ji, Yuan ^a   Schaid, Daniel J ^b   Desta, Zeruesenay ^c   Kubo, Michiaki ^d   Batzler, Anthony J ^b   Snyder, Karen ^b   Mushiroda, Taisei ^d   Kamatani, Naoyuki ^d   Ogburn, Evan ^c   Hall Flavin, Daniel ^b   Flockhart, David ^c   Nakamura, Yusuke ^e   Mrazek, David A ^b   Weinshilboum, Richard M ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c INDIANA UNIVERSITY   (United States)

^d RIKEN Center for Integrative Medical Sciences   (Japan)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

citalopram; escitalopram; genome wide association study; major depressive disorder; plasma drug concentration; selective serotonin reuptake inhibitor

Indexed keywords

CITALOPRAM; DRUG METABOLITE; ESCITALOPRAM; S DIDESMETHYLCITALOPRAM; UNCLASSIFIED DRUG; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; SEROTONIN UPTAKE INHIBITOR;

ADULT; ALLELE; ARTICLE; CHROMOSOME 10; CHROMOSOME 22; CLINICAL TRIAL (TOPIC); CORRELATIONAL STUDY; CYP2C19 GENE; CYP2D6 GENE; DRUG BLOOD LEVEL; DRUG TRANSFORMATION; FEMALE; GENE; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; HEREDITY; HUMAN; LINEAR SYSTEM; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PHARMACOGENOMICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BIOTRANSFORMATION; BLOOD; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; GENETICS; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOTRANSFORMATION; CITALOPRAM; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84904907494     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12348     Document Type: Article

References (31)

1. Lindsley CW,. The top prescription drugs of 2011 in the United States: antipsychotics and antidepressants once again lead CNS therapeutics. ACS Chem Neurosci 2012; 3: 630-631.
2. Lindsley CW,. The top prescription drugs of 2010 in the United States: antipsychotics show strong growth. ACS Chem Neurosci 2011; 2: 276-277.
3. Preskorn S, Staga C, Feighner J, Ross R, eds. Antidepressants: Past, Present and Future. Berlin-Heidelberg: Springer, 2004.
4. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T, Kuroiwa Y,. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997; 280: 927-933.
5. Rochat B, Amey M, Gillet M, Meyer UA, Baumann P,. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997; 7: 1-10.
6. von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI,. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001; 29: 1102-1109.
7. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Duan SX, Fogelman SM, Harmatz JS, Shader RI,. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry 1999; 46: 839-849.
8. Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P,. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology (Berl) 1996; 128: 421-425.
9. Yu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ, Zhou HH,. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos 2003; 31: 1255-1259.
10. Gutierrez M, Abramowitz W,. Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram. Pharmacotherapy 2001; 21: 163-168.
11. Gutierrez MM, Rosenberg J, Abramowitz W,. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003; 25: 1200-1210.
12. Hyttel J, Bogeso KP, Perregaard J, Sanchez C,. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992; 88: 157-160.
13. Olesen OV, Linnet K,. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 1999; 59: 298-309.
14. Foglia JP, Pollock BG, Kirshner MA, Rosen J, Sweet R, Mulsant B,. Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull 1997; 33: 109-112.
15. Voirol P, Rubin C, Bryois C, Kosel M, Buclin T, Baumann P,. Pharmacokinetic consequences of a citalopram treatment discontinuation. Ther Drug Monit 1999; 21: 263-266.
16. Kato M, Serretti A,. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010; 15: 473-500.
17. Serretti A, Artioli P,. The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J 2004; 4: 233-244.
18. Ji Y, Biernacka JM, Hebbring S, Chai Y, Jenkins GD, Batzler A, Snyder KA, Drews MS, Desta Z, Flockhart D, Mushiroda T, Kubo M, Nakamura Y, Kamatani N, Schaid D, Weinshilboum RM, Mrazek DA,. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J 2012; 13: 456-463.
19. Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Zeng Z, Schaid D, Mrazek DA, Kaddurah-Daouk R, Weinshilboum RM,. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-Informed pharmacogenomics. Clin Pharmacol Ther 2011; 89: 97-104.
20. Pritchard JK, Stephens M, Donnelly P,. Inference of population structure using multilocus genotype data. Genetics 2000; 155: 945-959.
21. Diggle P, Heagerty P, Liang K-Y, Zeger S, eds. Analysis of Longitudinal Data, 2nd edn. Oxford: Oxford University Press, 2002.
22. Sheiner LB, Rosenberg B, Marathe VV,. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445-479.
23. Leinonen E, Lepola U, Koponen H, Kinnunen I,. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit 1996; 18: 111-117.
24. Su WL, Sieberts SK, Kleinhanz RR, Lux K, Millstein J, Molony C, Schadt EE,. Assessing the prospects of genome-wide association studies performed in inbred mice. Mamm Genome 2010; 21: 143-152.
25. Baumann P, Larsen F,. The pharmacokinetics of citalopram. Rev Contemp Pharmocother 1996; 7: 287-295.
26. Herrlin K, Yasui-Furukori N, Tybring G, Widen J, Gustafsson LL, Bertilsson L,. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol 2003; 56: 415-421.
27. Sindrup SH, Brosen K, Hansen MG, Aaes-Jorgensen T, Overo KF, Gram LF,. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993; 15: 11-17.
28. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA,. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-15422.
29. Dayem Ullah AZ, Lemoine NR, Chelala C,. SNPnexus: a web server for functional annotation of novel and publicly known genetic variants (2012 update). Nucleic Acids Res 2012; 40: W65-70.
30. Moe OW,. Scaffolds: orchestrating proteins to achieve concerted function. Kidney Int 2003; 64: 1916-1917.
31. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis GR, Willer CJ,. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010; 26: 2336-2337.